{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:53:52Z","timestamp":1791262432258,"version":"4.1.0"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010031","name":"Postdoctoral Research Foundation of China","doi-asserted-by":"publisher","award":["2025M784506"],"award-info":[{"award-number":["2025M784506"]}],"id":[{"id":"10.13039\/501100010031","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Chikungunya virus (CHIKV) is primarily transmitted to humans through bites of infected\n                      <jats:italic>Aedes mosquitoes<\/jats:italic>\n                      , causing febrile illness as well as acute or chronic arthritis. With increasing reports in previously non-endemic regions, it poses an emerging threat to public health and a growing risk to travelers. Despite the recent approval of live-attenuated and virus-like particle-based vaccines, a safe, efficacious, and cost-effective vaccine remains urgently needed. The envelope glycoproteins E1 and E2, which play crucial roles in viral attachment and entry, are the major immunodominant structural proteins and can effectively elicit protective antibodies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We engineered mammalian cells to produce the ectodomains of the E1 and E2 glycoproteins and evaluated the protective efficacy of the resulting vaccine formulations\n                      <jats:italic>in vivo<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A two-dose vaccination regimen elicited high levels of antibodies and provided full protection against lethal challenge in A129 mice, preventing both death and joint swelling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These findings demonstrate the potential of this vaccine candidate against CHIKV and warrant its further development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1937609","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:25:10Z","timestamp":1791260710000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A subunit vaccine protects A129 mice from death and joint swelling against lethal Chikungunya virus challenge"],"prefix":"10.3389","volume":"17","author":[{"given":"Jiangfan","family":"Li","sequence":"first","affiliation":[{"name":"National Key Laboratory of Advanced Biotechnology, Academy of Military Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Fang","sequence":"additional","affiliation":[{"name":"National Key Laboratory of Advanced Biotechnology, Academy of Military Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyuan","family":"Song","sequence":"additional","affiliation":[{"name":"Laboratory of Advanced Biotechnology, ZJU-Hangzhou Global Scientific and Technological Innovation Center, Zhejiang University, Hangzhou","place":["Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Qiang","sequence":"additional","affiliation":[{"name":"National Key Laboratory of Advanced Biotechnology, Academy of Military Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yating","family":"Hu","sequence":"additional","affiliation":[{"name":"Laboratory of Advanced Biotechnology, ZJU-Hangzhou Global Scientific and Technological Innovation Center, Zhejiang University, Hangzhou","place":["Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanyi","family":"Zhao","sequence":"additional","affiliation":[{"name":"National Key Laboratory of Advanced Biotechnology, Academy of Military Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Wang","sequence":"additional","affiliation":[{"name":"National Key Laboratory of Advanced Biotechnology, Academy of Military Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Zhao","sequence":"additional","affiliation":[{"name":"National Key Laboratory of Advanced Biotechnology, Academy of Military Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangcheng","family":"Fu","sequence":"additional","affiliation":[{"name":"National Key Laboratory of Advanced Biotechnology, Academy of Military Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Yuan","sequence":"additional","affiliation":[{"name":"National Key Laboratory of Advanced Biotechnology, Academy of Military Medical Sciences","place":["Beijing, China"]},{"name":"Laboratory of Advanced Biotechnology, ZJU-Hangzhou Global Scientific and Technological Innovation Center, Zhejiang University, Hangzhou","place":["Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Li","sequence":"additional","affiliation":[{"name":"National Key Laboratory of Advanced Biotechnology, Academy of Military Medical Sciences","place":["Beijing, China"]},{"name":"Laboratory of Advanced Biotechnology, ZJU-Hangzhou Global Scientific and Technological Innovation Center, Zhejiang University, Hangzhou","place":["Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.scitotenv.2021.146128","article-title":"The ecophysiological plasticity of Aedes aegypti and Aedes albopictus concerning overwintering in cooler ecoregions is driven by local climate and acclimation capacity","volume":"778","author":"Kramer","year":"2021","journal-title":"Sci Total Environ"},{"key":"B2","doi-asserted-by":"publisher","first-page":"6973","DOI":"10.1038\/s41598-022-10977-4","article-title":"Impact of temperature on dengue and chikungunya transmission by the mosquito Aedes albopictus","volume":"12","author":"Mercier","year":"2022","journal-title":"Sci Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/insects14010049","article-title":"Global distribution of Aedes aegypti and Aedes albopictus in a climate change scenario of regional rivalry","volume":"14","author":"Laporta","year":"2023","journal-title":"Insects"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03703-w","article-title":"Global burden of chikungunya virus infections and the potential benefit of vaccination campaigns","volume":"31","author":"Ribeiro Dos Santos","year":"2025","journal-title":"Nat Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3201\/eid1212.060710","article-title":"Chikungunya disease outbreak, Reunion Island","volume":"12","author":"Josseran","year":"2006","journal-title":"Emerging Infect Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(23)00033-2","article-title":"Spatiotemporal dynamics and recurrence of chikungunya virus in Brazil: an epidemiological study","volume":"4","author":"de Souza","year":"2023","journal-title":"Lancet Microbe"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00029-X","article-title":"The deadly potential of chikungunya virus","volume":"24","author":"Salje","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1086\/590003","article-title":"Persistent arthralgia associated with chikungunya virus: a study of 88 adult patients on reunion island","volume":"47","author":"Borgherini","year":"2008","journal-title":"Clin Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007800","article-title":"Impact of Chikungunya virus infection on health status and quality of life: a retrospective cohort study","volume":"4","author":"Soumahoro","year":"2009","journal-title":"PloS One"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000389","article-title":"Post-epidemic Chikungunya disease on Reunion Island: course of rheumatic manifestations and associated factors over a 15-month period","volume":"3","author":"Sissoko","year":"2009","journal-title":"PloS NeglTrop Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2009.11.014","article-title":"Factors associated with persistence of arthralgia among Chikungunya virus-infected travellers: report of 42 French cases","volume":"47","author":"Larrieu","year":"2010","journal-title":"J Clin Virol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes015","article-title":"Impaired quality of life after chikungunya virus infection: a 2-year follow-up study","volume":"51","author":"Couturier","year":"2012","journal-title":"Rheumatol (Oxford)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001197","article-title":"The Chikungunya epidemic on La Reunion Island in 2005-2006: a cost-of-illness study","volume":"5","author":"Soumahoro","year":"2011","journal-title":"PloS NeglTrop Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2018.01.004","article-title":"Economic costs of Chikungunya virus in Colombia","volume":"17","author":"Alvis-Zakzuk","year":"2018","journal-title":"Value Health Reg Issues"},{"key":"B15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/0035-9203(55)90080-8","article-title":"An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952-53. I. Clinical features","volume":"49","author":"Robinson","year":"1955","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nature09555","article-title":"Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography","volume":"468","author":"Voss","year":"2010","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.04.006","article-title":"Cryo-EM structure of Chikungunya virus in complex with the Mxra8 receptor","volume":"177","author":"Basore","year":"2019","journal-title":"Cell"},{"key":"B18","doi-asserted-by":"publisher","first-page":"796","DOI":"10.3390\/v2040796","article-title":"Alphavirus entry and membrane fusion","volume":"2","author":"Kielian","year":"2010","journal-title":"Viruses"},{"key":"B19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41572-023-00429-2","article-title":"Chikungunya fever","volume":"9","author":"Bartholomeeusen","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"B20","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1017\/S0950268807008424","article-title":"Retrospective survey of Chikungunya disease in Reunion Island hospital staff","volume":"136","author":"Staikowsky","year":"2008","journal-title":"Epidemiol Infect"},{"key":"B21","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.cell.2024.01.033","article-title":"Live-attenuated chikungunya virus vaccine","volume":"187","author":"Ng","year":"2024","journal-title":"Cell"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/v17040550","article-title":"Inactivated viral vaccine BBV87 protects against Chikungunya virus challenge in a non-human primate model","volume":"17","author":"Kempster","year":"2025","journal-title":"Viruses"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010695","article-title":"Development of a next-generation chikungunya virus vaccine based on the HydroVax platform","volume":"18","author":"Slifka","year":"2022","journal-title":"PloS Pathog"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00372-1","article-title":"Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial","volume":"405","author":"Tindale","year":"2025","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)70043-5","article-title":"Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial","volume":"15","author":"Ramsauer","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.05.086","article-title":"A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus","volume":"31","author":"Brandler","year":"2013","journal-title":"Vaccine"},{"key":"B27","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41392-025-02182-2","article-title":"CHIKV mRNA vaccines encoding conserved structural\/envelope proteins confer broad cross-lineage protection against infection","volume":"10","author":"Liang","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.04.064","article-title":"A phase 1, randomized, placebo-controlled, dose-ranging study to evaluate the safety and immunogenicity of an mRNA-based chikungunya virus vaccine in healthy adults","volume":"41","author":"Shaw","year":"2023","journal-title":"Vaccine"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9040345","article-title":"Evaluation of DNA-launched virus-like particle vaccines in an immune competent mouse model of Chikungunya virus infection","volume":"9","author":"Rayner","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2012.05.004","article-title":"Subunit vaccine formulations based on recombinant envelope proteins of Chikungunya virus elicit balanced Th1\/Th2 response and virus-neutralizing antibodies in mice","volume":"167","author":"Khan","year":"2012","journal-title":"Virus Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/978-1-4939-3618-2_27","article-title":"Production of Chikungunya virus-like particles and subunit vaccines in insect cells","volume":"1426","author":"Metz","year":"2016","journal-title":"Methods Mol Biol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S567134","article-title":"Chikungunya virus in 2025: Epidemiology, immunopathogenesis, and vaccine development - a narrative review","volume":"19","author":"Zhao","year":"2026","journal-title":"Infect Drug Resist"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bsheal.2025.10.001","article-title":"Chikungunya virus: Current situation and future challenges","volume":"7","author":"Zhao","year":"2025","journal-title":"Biosaf Health"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00345-9","article-title":"Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: a phase 3, randomised, double-blind, placebo-controlled trial","volume":"405","author":"Richardson","year":"2025","journal-title":"Lancet"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1123805","article-title":"Platforms, advances, and technical challenges in virus-like particles-based vaccines","volume":"14","author":"Gupta","year":"2023","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2026.124000","article-title":"Adjuvant-free biopolymer particles mimicking the Chikungunya virus surface induce protective immunity","volume":"330","author":"Sivakumaran","year":"2026","journal-title":"Biomaterials"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2025.108193","article-title":"Genetic polymorphisms in the E2 glycoprotein of chikungunya virus (2014-2023) and their potential implications for immunity and vaccine design","volume":"163","author":"Fogaca","year":"2026","journal-title":"Int J Infect Dis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.83527","article-title":"Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus","volume":"2","author":"Roques","year":"2017","journal-title":"JCI Insight"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26093982","article-title":"Highly potent neutralizing nanobodies acting against Chikungunya virus infection via inhibiting multiple stages of the viral life cycle","volume":"26","author":"Song","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.10.050","article-title":"Broadly neutralizing alphavirus antibodies bind an epitope on E2 and inhibit entry and egress","volume":"163","author":"Fox","year":"2015","journal-title":"Cell"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01926-14","article-title":"Prime-boost immunization strategies against Chikungunya virus","volume":"88","author":"Hallengard","year":"2014","journal-title":"J Virol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.1c05975","article-title":"Expression, purification, and refolding of Chikungunya virus full-length envelope E2 protein along with B-cell and T-cell epitope analyses using immuno-informatics approaches","volume":"7","author":"Shukla","year":"2022","journal-title":"ACS Omega"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis033","article-title":"Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protection","volume":"205","author":"Kam","year":"2012","journal-title":"J Infect Dis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1586\/erv.12.84","article-title":"Chikungunya virus and prospects for a vaccine","volume":"11","author":"Weaver","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"B45","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nri705","article-title":"T(H)1 and T(H)2 cells: a historical perspective","volume":"2","author":"Liew","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2025.30.32.2500543","article-title":"Surveillance for adverse events following use of live attenuated chikungunya vaccine, United States, 2024, and the associated public health response in 2024 and 2025","volume":"30","author":"Hills","year":"2025","journal-title":"Euro Surveill"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2025.30.44.2500792","article-title":"Post-authorisation experience and reported adverse events following use of a virus-like particle chikungunya vaccine, United States and Germany, up to August 2025","volume":"30","author":"Simone","year":"2025","journal-title":"Euro Surveill"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1080\/21655979.2016.1191707","article-title":"Recent advances in the production of recombinant subunit vaccines in Pichia pastoris","volume":"7","author":"Wang","year":"2016","journal-title":"Bioengineered"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2014.912134","article-title":"Current advancements and potential strategies in the development of MERS-CoV vaccines","volume":"13","author":"Zhang","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01603-09","article-title":"Genome-scale phylogenetic analyses of chikungunya virus reveal independent emergences of recent epidemics and various evolutionary rates","volume":"84","author":"Volk","year":"2010","journal-title":"J Virol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.04.021","article-title":"Immunological implications of diverse production approaches for Chikungunya virus-like particle vaccines","volume":"40","author":"Thompson","year":"2022","journal-title":"Vaccine"},{"key":"B52","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41541-026-01413-z","article-title":"A chikungunya virus-like particle vaccine reduces chikungunya disease in cynomolgus macaques and protection is mediated by antibody transferred from vaccinated humans","volume":"11","author":"Coffey","year":"2026","journal-title":"NPJ Vaccines"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2105","article-title":"A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection","volume":"16","author":"Akahata","year":"2010","journal-title":"Nat Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002124","article-title":"Effective chikungunya virus-like particle vaccine produced in insect cells","volume":"7","author":"Metz","year":"2013","journal-title":"PloS NeglTrop Dis"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2014.05.038","article-title":"Monoclonal antibody targeting chikungunya virus envelope 1 protein inhibits virus release","author":"Masrinoul","year":"2014","journal-title":"Virology"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/emmm.201200213","article-title":"Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein","volume":"4","author":"Kam","year":"2012","journal-title":"EMBO Mol Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.chom.2015.06.009","article-title":"Isolation and characterization of broad and ultrapotent human monoclonal antibodies with therapeutic activity against Chikungunya virus","volume":"18","author":"Smith","year":"2015","journal-title":"Cell Host Microbe"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030263","article-title":"Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak","volume":"3","author":"Schuffenecker","year":"2006","journal-title":"PloS Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/s41598-018-19174-8","article-title":"Variation at position 350 in the Chikungunya virus 6K-E1 protein determines the sensitivity of detection in a rapid E1-antigen test","volume":"8","author":"Tuekprakhon","year":"2018","journal-title":"Sci Rep"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2009.06.017","article-title":"Development and evaluation of antigen capture ELISA for early clinical diagnosis of chikungunya","volume":"65","author":"Shukla","year":"2009","journal-title":"Diagn Microbiol Infect Dis"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.09.045","article-title":"Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits","volume":"31","author":"Metz","year":"2013","journal-title":"Vaccine"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-022-07651-3","article-title":"Expression of mammalian proteins for diagnostics and therapeutics: a review","volume":"49","author":"Mark","year":"2022","journal-title":"Mol Biol Rep"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1093\/database\/baab012","article-title":"Posttranslational modifications in proteins: resources, tools and prediction methods","volume":"2021","author":"Ramazi","year":"2021","journal-title":"Database (Oxford)"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-8-353","article-title":"Functional processing and secretion of Chikungunya virus E1 and E2 glycoproteins in insect cells","volume":"8","author":"Metz","year":"2011","journal-title":"Virol J"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.07.072","article-title":"Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus","volume":"30","author":"Kumar","year":"2012","journal-title":"Vaccine"},{"key":"B66","doi-asserted-by":"publisher","first-page":"198","DOI":"10.4161\/bioe.28336","article-title":"Immunogenicity of Escherichia coli expressed envelope 2 protein of Chikungunya virus","volume":"5","author":"Tripathi","year":"2014","journal-title":"Bioengineered"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-013-5426-4","article-title":"Production of recombinant Chikungunya virus envelope 2 protein in Escherichia coli","volume":"98","author":"Tripathi","year":"2014","journal-title":"Appl Microbiol Biotechnol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003684","article-title":"A small antigenic determinant of the Chikungunya virus E2 protein is sufficient to induce neutralizing antibodies which are partially protective in mice","volume":"9","author":"Weber","year":"2015","journal-title":"PloS NeglTrop Dis"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1500622","article-title":"Assessment of heat-killed E. coli expressing Chikungunya virus E2 protein as a candidate vaccine for dual protection against Chikungunya virus and E. coli","volume":"15","author":"Patra","year":"2024","journal-title":"Front Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1557415","article-title":"The recent advances in vaccine adjuvants","volume":"16","author":"Xing","year":"2025","journal-title":"Front Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.2477","article-title":"Effect of a chikungunya virus-like particle vaccine on safety and tolerability outcomes: A randomized clinical trial","volume":"323","author":"Chen","year":"2020","journal-title":"JAMA"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging concepts in the science of vaccine adjuvants","volume":"20","author":"Pulendran","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/srep39475","article-title":"Central role of CD169(+) lymph node resident macrophages in the adjuvanticity of the QS-21 component of AS01","volume":"6","author":"Detienne","year":"2016","journal-title":"Sci Rep"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14071455","article-title":"Using dual Toll-like receptor agonism to drive Th1-biased response in a squalene- and alpha-Tocopherol-containing emulsion for a more effective SARS-CoV-2 vaccine","volume":"14","author":"Short","year":"2022","journal-title":"Pharmaceutics"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1937609\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:25:12Z","timestamp":1791260712000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1937609\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":74,"alternative-id":["10.3389\/fimmu.2026.1937609"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1937609","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"article-number":"1937609"}}